Needham analyst Gil Blum maintained a Buy rating on Celcuity (CELC – Research Report) today and set a price target of $50.00. The company's shares closed last Wednesday at $8.04, close to its 52-week low of $7.72. According to TipRanks.com, Blum has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -27.4% and a 25.5% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Crispr Therapeutics AG, and Aeglea Biotherapeutics. Celcuity has an analyst consensus of Moderate Buy, with a price target consensus of $50.00.
https://www.tipranks.com/news/blurbs/needham-thinks-celcuitys-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Celcuity (NASDAQ:CELC)
Gráfico Histórico do Ativo
De Jul 2022 até Ago 2022 Click aqui para mais gráficos Celcuity.
Celcuity (NASDAQ:CELC)
Gráfico Histórico do Ativo
De Ago 2021 até Ago 2022 Click aqui para mais gráficos Celcuity.